United KingdomA general practitioner in the UK reports that the rollout of GLP-1 pills for weight management has underperformed, with only 6% of injection users switching to tablets. Dr. Adam Staten notes that while many expected the pills to revolutionize weight loss treatment, they have not gained significant traction. He attributes this to factors such as the need for strict dietary restrictions with tablets, comparable pricing to injections, and reported side effects like gastrointestinal issues. Patients remain more comfortable with injections due to their convenience and established track record of success. The pills were approved by the MHRA in June 2026 and became available in pharmacies shortly thereafter.
Bias read (Center): The article presents a balanced account of the situation, focusing on clinical observations and patient preferences rather than political advocacy. While it highlights concerns about the effectiveness and appeal of GLP-1 pills, it does not take a clear ideological stance or promote specific policies
